Drug intelligence / Profile preview

Haima Bushen Wan

Development stage: Unknown
Lead developer: Sinopharm Lerentang
Administration: Oral

Overview

Haima Bushen Wan (海马补肾丸) is a traditional Chinese medicine (TCM) herbal formula developed and manufactured by Hebei Lerentang Medicine, a subsidiary of the Daren Tang group. Formulated as an oral pill, it is primarily indicated for the treatment of kidney deficiency and as a renal tonic according to traditional TCM principles. The formula is a complex mixture of multiple ingredients, including seahorse (Haima) and epimedium, which are traditionally utilized to tonify kidney yang. As a multi-herb TCM product, its specific molecular targets and pharmacological mechanisms in Western medical terms are not well-defined, although it is an established and award-winning product within the company's marketed portfolio.

Brand names: Haima Bushen Wan海马补肾丸
Other names: Seahorse Kidney Tonifying PillsHaima Bushen Pill

Beyond the preview

Go deeper on Haima Bushen Wan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Haima Bushen Wan.

Explore the full profile